Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04154670
Recruitment Status : Completed
First Posted : November 6, 2019
Last Update Posted : June 23, 2020
Sponsor:
Information provided by (Responsible Party):
Magenta Therapeutics, Inc.

Brief Summary:
This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).

Condition or disease Intervention/treatment Phase
Healthy Renal Insufficiency Biological: MGTA-145 Phase 1

Detailed Description:
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
Actual Study Start Date : November 7, 2019
Actual Primary Completion Date : March 24, 2020
Actual Study Completion Date : March 24, 2020

Arm Intervention/treatment
Experimental: Normal kidney function
MGTA-145 single dose
Biological: MGTA-145
MGTA-145 will be given intravenously

Experimental: Mild decrease in GFR
MGTA-145 single dose
Biological: MGTA-145
MGTA-145 will be given intravenously

Experimental: Moderate decrease in GFR
MGTA-145 single dose
Biological: MGTA-145
MGTA-145 will be given intravenously




Primary Outcome Measures :
  1. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    Investigate area under the curve (AUC)

  2. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    Investigate maximum plasma concentration (Cmax)

  3. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    Investigate clearance (CL)

  4. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    volume of distribution at steady state (Vdss)

  5. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    Investigate half-life

  6. Pharmacokinetics Biomarkers [ Time Frame: 2 days ]
    Investigate renal clearance of MGTA-145


Secondary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: 15 days ]
    Investigate the safety and tolerability of MGTA-145 following intravenous (IV) administration as monotherapy in subjects with varying degrees of renal impairment (e.g. adverse events, clinical laboratory tests, vital signs, ECGs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria for all subjects:

  1. Age from 18 to 79 years, inclusive, at the time of signing of the ICF.
  2. Body weight ≥50 kg and BMI 19 to 40 kg/m2, inclusive.
  3. Systolic blood pressure ≤170 mmHg and diastolic blood pressure ≤100 mmHg at Screening and Day 1.
  4. No clinically significant abnormalities on physical examination at Screening.
  5. Alanine aminotransferase and aspartate aminotransferase up to 1.5 x the upper limit of normal (ULN) as long as total bilirubin and alkaline phosphatase are ≤ ULN.
  6. No clinically significant abnormalities on ECG and QTcF <480 msec at Screening.
  7. Female subjects are not pregnant, non-lactating, and must be of non-childbearing potential being either surgically sterile (eg, documented hysterectomy, bilateral oophorectomy, bilateral salpingo oopherectomy, tubal ligation) or post-menopausal women (over 45 years of age with 12 months or more amenorrhea verified by follicle stimulating hormone assessment and the absence of other biological or physiological causes).
  8. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or those who are sexually active with a female partner(s) and agree to use an acceptable method of contraception (such as condom with spermicide) combined with an acceptable method of contraception for their non-pregnant female partner(s) after informed consent, throughout the study, and for a minimum of 90 days after the last dose, and who do not intend to donate sperm in the period from Screening until 3 months following administration of the study drug.
  9. Subject using medications known to affect the elimination of serum creatinine (eg, cimetidine, trimethoprim) within the past 30 days.
  10. Capable of providing informed consent and willing to comply with the requirements of the protocol.

    Specific inclusion criteria for subjects with NORMAL renal function:

  11. Estimated GFR (based on MDRD equation) ≥90 mL/min/1.73 m2 (normal) as determined by an average of 2 values obtained at least 48 hours apart within the previous 3 months.
  12. White blood cell (WBC) count, hemoglobin and platelet count within normal limits. Absolute neutrophil count of >1500/µL for African Americans and >2000/µL for other races.

    Specific inclusion criteria for subjects with RENAL IMPAIRMENT:

  13. Estimated GFR <90 mL/min/1.73 m2 (based on MDRD equation) as determined by an average of 2 values obtained at least 48 hours apart and within the previous 3 months.
  14. Stable renal function as determined by <20% difference in serum creatinine obtained on 2 occasions at least 48 hours apart and within the previous 3 months.
  15. Platelet count ≥100,000/mm3, hemoglobin count ≥10g/dL, WBC count within normal limits. Absolute neutrophil count of >1500/µL for African Americans and >2000/µL for other races.

Exclusion criteria for all subjects:

  1. Clinically significant abnormal finding on physical examination conducted at Screening. The assessment may be repeated once prior to treatment number assignment. If the repeat value(s) remains outside of protocol-specified ranges, the subject will be excluded from the study. Note: Re assessment is not allowed for subjects who have a positive urine drug screen test at Screening.
  2. History of chronic alcohol or drug abuse within the previous 12 months. Subject has a positive pre-study drug/alcohol screen (to include at minimum: amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepines, and myelosuppressive drugs). A subject with a positive finding on the drug screen may still be enrolled at the discretion of the Investigator if a plausible clinical explanation exists (eg, prior or concomitant medication use).
  3. History of kidney transplantation or requiring dialysis or anticipated to initiate dialysis during the study period.
  4. Donation of more than 500 mL of blood or plasma within 12 weeks prior to dosing.
  5. Subject smokes more than 10 cigarettes per day (or equivalent) or has done so within 6 months prior to the Screening Visit.
  6. Acute illness, infection (requiring medical treatment [eg, antibiotics]), or surgery within 30 days of dosing.
  7. Seropositive for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus.
  8. Subject has received another investigational drug or participated in an investigational device study within 30 days prior to dosing.
  9. History of anaphylaxis or clinically important reaction to any drug including plerixafor.

    Specific exclusion criteria for subjects with NORMAL renal function:

  10. Any clinically significant laboratory value outside the normal range at Screening. The assessment may be repeated once prior to treatment number assignment. If the repeat value(s) remains outside of protocol-specified ranges, the subject will be excluded from the study. Note: Re assessment is not allowed for subjects who have a positive urine drug screen test at Screening.
  11. Any clinically significant hematologic, cardiovascular, pulmonary, central nervous system, metabolic, hepatic, or gastrointestinal conditions or history of conditions that, in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this study or may interfere with the interpretation of the study results.
  12. Subject has used any prescription drugs within 14 days prior to dosing or any dietary supplements or non prescription drugs within 7 days prior to dosing unless deemed acceptable by the Investigator and Sponsor (Magenta Medical Monitor).

    Specific exclusion criteria for subjects with RENAL IMPAIRMENT:

  13. Presence of acute kidney injury.
  14. Clinically significant laboratory abnormalities excluding those associated with renal impairment or the underlying cause of renal disease.
  15. Unstable medical condition or underlying medical condition that has changed within the past 90 days.
  16. Presence of laboratory abnormalities or clinically significant medical condition that in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this study or may interfere with the interpretation of the study results.
  17. Changes in prescription medications within 14 days prior to dosing or anticipated changes during the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04154670


Locations
Layout table for location information
United States, Florida
Orlando Clinical Research Center (OCRC)
Orlando, Florida, United States, 32809
United States, Tennessee
Alliance for Multispeciality Research (AMR) Formerly New Orleans Center for Clinical Research (NOCCR)
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Magenta Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Will Savage, MD, PhD Magenta Therapeutics
Layout table for additonal information
Responsible Party: Magenta Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04154670    
Other Study ID Numbers: 145-RI-102
First Posted: November 6, 2019    Key Record Dates
Last Update Posted: June 23, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases